PuSH - Publikationsserver des Helmholtz Zentrums München

Siehler, J. ; Blöchinger, A. ; Meier, M. ; Lickert, H.

Engineering islets from stem cells for advanced therapies of diabetes.

Nat. Rev. Drug Discov. 20, 920–940 (2021)
Postprint DOI PMC
Open Access Green
Diabetes mellitus is a metabolic disorder that affects more than 460 million people worldwide. Type 1 diabetes (T1D) is caused by autoimmune destruction of β-cells, whereas type 2 diabetes (T2D) is caused by a hostile metabolic environment that leads to β-cell exhaustion and dysfunction. Currently, first-line medications treat the symptomatic insulin resistance and hyperglycaemia, but do not prevent the progressive decline of β-cell mass and function. Thus, advanced therapies need to be developed that either protect or regenerate endogenous β-cell mass early in disease progression or replace lost β-cells with stem cell-derived β-like cells or engineered islet-like clusters. In this Review, we discuss the state of the art of stem cell differentiation and islet engineering, reflect on current and future challenges in the area and highlight the potential for cell replacement therapies, disease modelling and drug development using these cells. These efforts in stem cell and regenerative medicine will lay the foundations for future biomedical breakthroughs and potentially curative treatments for diabetes.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Insulin-producing Cells; Pancreatic Beta-cells; Mesenchymal Stromal Cells; Development Success Rates; In-vitro; Progenitor Cells; Alpha-cell; Endocrine Pancreas; Edmonton Protocol; Secreting Cells
ISSN (print) / ISBN 1474-1776
Zeitschrift Nature Reviews - Drug Discovery
Quellenangaben Band: 20, Heft: , Seiten: 920–940 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Regeneration Research (IDR)
Helmholtz Pioneer Campus (HPC)
Förderungen Technical University Munich
Helmholtz Association
German Center for Diabetes Research (DZD e.V.)
German Federal Ministry of Education and Research (BMBF)
European Union